Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week study of AF-219 in treatment-refractory chronic cough
2015-005064-42Phase 2Completed
- Sponsor
- Afferent Pharmaceuticals, Inc.
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gefapixant in chronic cough (4 arms), sponsored by Afferent Pharmaceuticals, Inc. Primary endpoint: Change from baseline in awake objective cough frequency at Week 12. Started Dec 2015; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on 2015-005064-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005064-42.